Cargando…

Impact of Amoxicillin-Clavulanate followed by Autologous Fecal Microbiota Transplantation on Fecal Microbiome Structure and Metabolic Potential

Strategies to prevent multidrug-resistant organism (MDRO) infections are scarce, but autologous fecal microbiota transplantation (autoFMT) may limit gastrointestinal MDRO expansion. AutoFMT involves banking one’s feces during a healthy state for later use in restoring gut microbiota following pertur...

Descripción completa

Detalles Bibliográficos
Autores principales: Bulow, Christopher, Langdon, Amy, Hink, Tiffany, Wallace, Meghan, Reske, Kimberly A., Patel, Sanket, Sun, Xiaoqing, Seiler, Sondra, Jones, Susan, Kwon, Jennie H., Burnham, Carey-Ann D., Dantas, Gautam, Dubberke, Erik R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6249645/
https://www.ncbi.nlm.nih.gov/pubmed/30463925
http://dx.doi.org/10.1128/mSphereDirect.00588-18
_version_ 1783372787212091392
author Bulow, Christopher
Langdon, Amy
Hink, Tiffany
Wallace, Meghan
Reske, Kimberly A.
Patel, Sanket
Sun, Xiaoqing
Seiler, Sondra
Jones, Susan
Kwon, Jennie H.
Burnham, Carey-Ann D.
Dantas, Gautam
Dubberke, Erik R.
author_facet Bulow, Christopher
Langdon, Amy
Hink, Tiffany
Wallace, Meghan
Reske, Kimberly A.
Patel, Sanket
Sun, Xiaoqing
Seiler, Sondra
Jones, Susan
Kwon, Jennie H.
Burnham, Carey-Ann D.
Dantas, Gautam
Dubberke, Erik R.
author_sort Bulow, Christopher
collection PubMed
description Strategies to prevent multidrug-resistant organism (MDRO) infections are scarce, but autologous fecal microbiota transplantation (autoFMT) may limit gastrointestinal MDRO expansion. AutoFMT involves banking one’s feces during a healthy state for later use in restoring gut microbiota following perturbation. This pilot study evaluated the effect of autoFMT on gastrointestinal microbiome taxonomic composition, resistance gene content, and metabolic capacity after exposure to amoxicillin-clavulanic acid (Amox-Clav). Ten healthy participants were enrolled. All received 5 days of Amox-Clav. Half were randomized to autoFMT, derived from stool collected pre-antimicrobial exposure, by enema, and half to saline enema. Participants submitted stool samples pre- and post-Amox-Clav and enema and during a 90-day follow-up period. Shotgun metagenomic sequencing revealed taxonomic composition, resistance gene content, and metabolic capacity. Amox-Clav significantly altered gut taxonomic composition in all participants (n = 10, P < 0.01); however, only three participants exhibited major changes at the phylum level following exposure. In the cohort as a whole, beta-lactamase genes were enriched following Amox-Clav (P < 0.05), and predicted metabolic capacity was significantly altered (P < 0.01). Species composition, metabolic capacity, and beta-lactamase abundance returned to pre-antimicrobial exposure state 7 days after either autoFMT or saline enema (P > 0.05, compared to enrollment). Alterations to microbial metabolic capacity occurred following antimicrobial exposure even in participants without substantial taxonomic disruption, potentially creating open niches for pathogen colonization. Our findings suggest that metabolic potential is an important consideration for complete assessment of antimicrobial impact on the microbiome. AutoFMT was well tolerated and may have contributed to phylogenetic recovery. (This study has been registered at ClinicalTrials.gov under identifier NCT02046525.) IMPORTANCE The spread of multidrug resistance among pathogenic organisms threatens the efficacy of antimicrobial treatment options. The human gut serves as a reservoir for many drug-resistant organisms and their resistance genes, and perturbation of the gut microbiome by antimicrobial exposure can open metabolic niches to resistant pathogens. Once established in the gut, antimicrobial-resistant bacteria can persist even after antimicrobial exposure ceases. Strategies to prevent multidrug-resistant organism (MDRO) infections are scarce, but autologous fecal microbiota transplantation (autoFMT) may limit gastrointestinal MDRO expansion. AutoFMT involves banking one’s feces during a healthy state for later use in restoring gut microbiota following perturbation. This pilot study evaluated the effect of amoxicillin-clavulanic acid (Amox-Clav) exposure and autoFMT on gastrointestinal microbiome taxonomic composition, resistance gene content, and metabolic capacity. Importantly, we found that metabolic capacity was perturbed even in cases where gross phylogeny remained unchanged and that autoFMT was safe and well tolerated.
format Online
Article
Text
id pubmed-6249645
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-62496452018-11-30 Impact of Amoxicillin-Clavulanate followed by Autologous Fecal Microbiota Transplantation on Fecal Microbiome Structure and Metabolic Potential Bulow, Christopher Langdon, Amy Hink, Tiffany Wallace, Meghan Reske, Kimberly A. Patel, Sanket Sun, Xiaoqing Seiler, Sondra Jones, Susan Kwon, Jennie H. Burnham, Carey-Ann D. Dantas, Gautam Dubberke, Erik R. mSphere Research Article Strategies to prevent multidrug-resistant organism (MDRO) infections are scarce, but autologous fecal microbiota transplantation (autoFMT) may limit gastrointestinal MDRO expansion. AutoFMT involves banking one’s feces during a healthy state for later use in restoring gut microbiota following perturbation. This pilot study evaluated the effect of autoFMT on gastrointestinal microbiome taxonomic composition, resistance gene content, and metabolic capacity after exposure to amoxicillin-clavulanic acid (Amox-Clav). Ten healthy participants were enrolled. All received 5 days of Amox-Clav. Half were randomized to autoFMT, derived from stool collected pre-antimicrobial exposure, by enema, and half to saline enema. Participants submitted stool samples pre- and post-Amox-Clav and enema and during a 90-day follow-up period. Shotgun metagenomic sequencing revealed taxonomic composition, resistance gene content, and metabolic capacity. Amox-Clav significantly altered gut taxonomic composition in all participants (n = 10, P < 0.01); however, only three participants exhibited major changes at the phylum level following exposure. In the cohort as a whole, beta-lactamase genes were enriched following Amox-Clav (P < 0.05), and predicted metabolic capacity was significantly altered (P < 0.01). Species composition, metabolic capacity, and beta-lactamase abundance returned to pre-antimicrobial exposure state 7 days after either autoFMT or saline enema (P > 0.05, compared to enrollment). Alterations to microbial metabolic capacity occurred following antimicrobial exposure even in participants without substantial taxonomic disruption, potentially creating open niches for pathogen colonization. Our findings suggest that metabolic potential is an important consideration for complete assessment of antimicrobial impact on the microbiome. AutoFMT was well tolerated and may have contributed to phylogenetic recovery. (This study has been registered at ClinicalTrials.gov under identifier NCT02046525.) IMPORTANCE The spread of multidrug resistance among pathogenic organisms threatens the efficacy of antimicrobial treatment options. The human gut serves as a reservoir for many drug-resistant organisms and their resistance genes, and perturbation of the gut microbiome by antimicrobial exposure can open metabolic niches to resistant pathogens. Once established in the gut, antimicrobial-resistant bacteria can persist even after antimicrobial exposure ceases. Strategies to prevent multidrug-resistant organism (MDRO) infections are scarce, but autologous fecal microbiota transplantation (autoFMT) may limit gastrointestinal MDRO expansion. AutoFMT involves banking one’s feces during a healthy state for later use in restoring gut microbiota following perturbation. This pilot study evaluated the effect of amoxicillin-clavulanic acid (Amox-Clav) exposure and autoFMT on gastrointestinal microbiome taxonomic composition, resistance gene content, and metabolic capacity. Importantly, we found that metabolic capacity was perturbed even in cases where gross phylogeny remained unchanged and that autoFMT was safe and well tolerated. American Society for Microbiology 2018-11-21 /pmc/articles/PMC6249645/ /pubmed/30463925 http://dx.doi.org/10.1128/mSphereDirect.00588-18 Text en Copyright © 2018 Bulow et al. https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Article
Bulow, Christopher
Langdon, Amy
Hink, Tiffany
Wallace, Meghan
Reske, Kimberly A.
Patel, Sanket
Sun, Xiaoqing
Seiler, Sondra
Jones, Susan
Kwon, Jennie H.
Burnham, Carey-Ann D.
Dantas, Gautam
Dubberke, Erik R.
Impact of Amoxicillin-Clavulanate followed by Autologous Fecal Microbiota Transplantation on Fecal Microbiome Structure and Metabolic Potential
title Impact of Amoxicillin-Clavulanate followed by Autologous Fecal Microbiota Transplantation on Fecal Microbiome Structure and Metabolic Potential
title_full Impact of Amoxicillin-Clavulanate followed by Autologous Fecal Microbiota Transplantation on Fecal Microbiome Structure and Metabolic Potential
title_fullStr Impact of Amoxicillin-Clavulanate followed by Autologous Fecal Microbiota Transplantation on Fecal Microbiome Structure and Metabolic Potential
title_full_unstemmed Impact of Amoxicillin-Clavulanate followed by Autologous Fecal Microbiota Transplantation on Fecal Microbiome Structure and Metabolic Potential
title_short Impact of Amoxicillin-Clavulanate followed by Autologous Fecal Microbiota Transplantation on Fecal Microbiome Structure and Metabolic Potential
title_sort impact of amoxicillin-clavulanate followed by autologous fecal microbiota transplantation on fecal microbiome structure and metabolic potential
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6249645/
https://www.ncbi.nlm.nih.gov/pubmed/30463925
http://dx.doi.org/10.1128/mSphereDirect.00588-18
work_keys_str_mv AT bulowchristopher impactofamoxicillinclavulanatefollowedbyautologousfecalmicrobiotatransplantationonfecalmicrobiomestructureandmetabolicpotential
AT langdonamy impactofamoxicillinclavulanatefollowedbyautologousfecalmicrobiotatransplantationonfecalmicrobiomestructureandmetabolicpotential
AT hinktiffany impactofamoxicillinclavulanatefollowedbyautologousfecalmicrobiotatransplantationonfecalmicrobiomestructureandmetabolicpotential
AT wallacemeghan impactofamoxicillinclavulanatefollowedbyautologousfecalmicrobiotatransplantationonfecalmicrobiomestructureandmetabolicpotential
AT reskekimberlya impactofamoxicillinclavulanatefollowedbyautologousfecalmicrobiotatransplantationonfecalmicrobiomestructureandmetabolicpotential
AT patelsanket impactofamoxicillinclavulanatefollowedbyautologousfecalmicrobiotatransplantationonfecalmicrobiomestructureandmetabolicpotential
AT sunxiaoqing impactofamoxicillinclavulanatefollowedbyautologousfecalmicrobiotatransplantationonfecalmicrobiomestructureandmetabolicpotential
AT seilersondra impactofamoxicillinclavulanatefollowedbyautologousfecalmicrobiotatransplantationonfecalmicrobiomestructureandmetabolicpotential
AT jonessusan impactofamoxicillinclavulanatefollowedbyautologousfecalmicrobiotatransplantationonfecalmicrobiomestructureandmetabolicpotential
AT kwonjennieh impactofamoxicillinclavulanatefollowedbyautologousfecalmicrobiotatransplantationonfecalmicrobiomestructureandmetabolicpotential
AT burnhamcareyannd impactofamoxicillinclavulanatefollowedbyautologousfecalmicrobiotatransplantationonfecalmicrobiomestructureandmetabolicpotential
AT dantasgautam impactofamoxicillinclavulanatefollowedbyautologousfecalmicrobiotatransplantationonfecalmicrobiomestructureandmetabolicpotential
AT dubberkeerikr impactofamoxicillinclavulanatefollowedbyautologousfecalmicrobiotatransplantationonfecalmicrobiomestructureandmetabolicpotential